Complications of brain tumors and their treatment

Hematology/Oncology Clinics of North America

Volumn 26, Issue 4, 2012, Pages 779-796

  Lacy, Jill ^a   Saadati, Hamid ^a   Yu, James B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiepileptic drugs; Corticosteroids; Pseudoprogression; Radiation related toxicities; Seizures; Vasogenic edema; Venous thromboembolic disease

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; DONEPEZIL; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; LOW MOLECULAR WEIGHT HEPARIN; METHYLPHENIDATE; PREGABALIN; TEMOZOLOMIDE; TOPIRAMATE; VASCULOTROPIN; WARFARIN;

ACNE; ANTICOAGULANT THERAPY; ANTICONVULSANT THERAPY; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CATARACT; CHEMORADIOTHERAPY; CLINICAL FEATURE; COLON DIVERTICULOSIS; CORTICOSTEROID INDUCED MYOPATHY; CORTICOSTEROID THERAPY; DELIRIUM; DIABETES MELLITUS; DIFFUSION WEIGHTED IMAGING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; FLUID RETENTION; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLIOBLASTOMA; HICCUP; HUMAN; HYPERBARIC OXYGEN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INCREASED APPETITE; INFECTION; INFECTIOUS COMPLICATION; INSOMNIA; INTESTINE PERFORATION; LYMPHOCYTOPENIA; MENTAL HEALTH; MENTAL INSTABILITY; MOON FACE; NEUROIMAGING; OLIGODENDROGLIOMA; OSTEOPENIA; PEPTIC ULCER; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; PURPURA; RADIATION NECROSIS; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SIDE EFFECT; SKIN FRAGILITY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREMOR; VASOGENIC EDEMA; VENOUS THROMBOEMBOLISM; WEAKNESS; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; BRAIN EDEMA; BRAIN NEOPLASMS; HUMANS; RADIOTHERAPY; SEIZURES; THROMBOEMBOLISM;

EID: 84863880201     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.04.007     Document Type: Review

References (95)

1. Bertossi M., Virgintino D., Maiorano E., et al. Ultrastructural and morphometric investigation of human brain capillaries in normal and peritumoral tissues. Ultrastruct Pathol 1997, 21:41-49.
2. Boucher Y., Salehi H., Witwer B., et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 1997, 75:829-836.
3. Strugar J.G., Criscuolo G.R., Rothbart D., et al. Vascular endothelial growth/permeability factor expression in human glioma specimens: correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 1995, 83:682-689.
4. Dobrogowska D.H., Lossinsky A.S., Tarnawski M., et al. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor. J Neurocytol 1998, 27:163-173.
5. Machein M.R., Kullmer J., Fiebich B.L., et al. Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery 1999, 44:732-740.
6. Carlson M.R., Pope W.B., Horvath S., et al. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007, 13:2592-2598.
7. Gerstner E.R., Duda D.G., di Tomaso E., et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009, 6:229-236.
8. Chan A.S., Leung S.Y., Wong M.P., et al. Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 1998, 22:816-826.
9. Jarden J.O., Dhawan V., Moeller J.R., et al. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study. Ann Neurol 1989, 25:239-245.
10. Sinha S., Bastin M.E., Wardlaw J.M., et al. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry 2004, 75:1632-1635.
11. Kim H., Lee J.M., Park J.S., et al. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun 2008, 372:243-248.
12. Heiss J.D., Papavassiliou E., Merrill M.J., et al. Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 1996, 98:1400-1408.
13. Ryken T.C., McDermott M., Robinson P.D., et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:103-114.
14. Vecht C.J., Hovestadt A., Verbiest H.B., et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994, 44:675-680.
15. Hempen C., Weiss E., Hess C.F. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects?. Support Care Cancer 2002, 10:322-328.
16. Sturdza A., Millar B.A., Bana N., et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008, 16:1041-1048.
17. Dropcho E.J., Soong S.J. Steroid-induced weakness in patients with primary brain tumors. Neurology 1991, 41:1235-1239.
18. Henson J.W., Jalaj J.K., Walker R.W., et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991, 48:406-409.
19. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996, 27:235.
20. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375-1382.
21. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991, 114:735-740.
22. Weiner H.L., Rezai A.R., Cooper P.R. Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids. Neurosurgery 1993, 33:40-43.
23. ReMine S.G., McIlrath D.C. Bowel perforation in steroid-treated patients. Ann Surg 1980, 192:581-586.
24. Kamoun W.S., Ley C.D., Farrar C.T., et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009, 27:2542-2552.
25. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
26. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
27. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
28. Batchelor T.T., Duda D.G., di Tomaso E., et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010, 28:2817-2823.
29. Nowosielski M., Recheis W., Goebel G., et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 2011, 53:291-302.
30. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005, 6:401-410.
31. Jenkins E.O., Schiff D., Mackman N., et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010, 8:221-227.
32. Gerber D.E., Grossman S.A., Streiff M.B. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006, 24:1310-1318.
33. Marras L.C., Geerts W.H., Perry J.R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000, 89:640-646.
34. Simanek R., Vormittag R., Hassler M., et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 2007, 9:89-95.
35. Lazio B.E., Simard J.M. Anticoagulation in neurosurgical patients. Neurosurgery 1999, 45:838-847.
36. Lyman G.H., Khorana A.A., Falanga A., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25:5490-5505.
37. Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005, 106:4027-4033.
38. Noble S.I., Shelley M.D., Coles B., et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008, 9:577-584.
39. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl 6):454S-545S.
40. Ruff R.L., Posner J.B. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983, 13:334-336.
41. Levin J.M., Schiff D., Loeffler J.S., et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993, 43:1111-1114.
42. Monreal M., Zacharski L., Jiménez J.A., et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004, 2:1311-1315.
43. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
44. Akl E.A., Labedi N., Barba M., et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011, 6. CD006650.
45. Nghiemphu P.L., Green R.M., Pope W.B., et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008, 10:355-360.
46. Perry J.R., Julian J.A., Laperriere N.J., et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010, 8:1959-1965.
47. van Breemen M.S., Wilms E.B., Vecht C.J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007, 6:421-430.
48. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54(10):1886-1893.
49. Lote K., Stenwig A.E., Skullerud K., et al. Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 1998, 34:98-102.
50. Pace A., Bove L., Innocenti P., et al. Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998, 17:479-482.
51. Oberndorfer S., Schmal T., Lahrmann H., et al. Wien Klin Wochenschr 2002, 114(21-22):911-916. [in German].
52. Cascino G.D. Epilepsy and brain tumors: implications for treatment. Epilepsia 1990, 31(Suppl 3):S37-S44.
53. Cavaliere R., Farace E., Schiff D. Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol 2006, 63:1746-1749.
54. Karceski S., Morrell M.J., Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005, 7(Suppl 1):S1-S64.
55. Vecht C.J., Wagner G.L., Wilms E.B. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003, 2:404-409.
56. Rosati A., Buttolo L., Stefini R., et al. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 2010, 67:343-346.
57. Usery J.B., Michael L.M., Sills A.K., et al. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 2010, 99:251-260.
58. Mamon H.J., Wen P.Y., Burns A.C., et al. Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 1999, 40:341-344.
59. Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999, 353(9171):2190-2194.
60. Delattre J.Y., Safai B., Posner J.B. Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 1988, 38:194-198.
61. Khafaga Y.M., Jamshed A., Allam A.A., et al. Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy. Acta Oncol 1999, 38:111-116.
62. Phi J.H., Kim S.K., Cho B.K., et al. Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. Cancer 2009, 115:5771-5779.
63. Luyken C., Blümcke I., Fimmers R., et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 2003, 44:822-830.
64. Chalifoux R., Elisevich K. Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumors. Stereotact Funct Neurosurg 1996-1997, 67(3-4):169-182.
65. Rogers L.R., Morris H.H., Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 1993, 43:1599-1601.
66. Pace A., Vidiri A., Galiè E., et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 2003, 14:1722-1726.
67. Sherman J.H., Moldovan K., Yeoh H.K., et al. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg 2011, 114:1617-1621.
68. Sirven J.I., Wingerchuk D.M., Drazkowski J.F., et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004, 79:1489-1494.
69. Kuijlen J.M., Teernstra O.P., Kessels A.G., et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996, 5:291-298.
70. Merchant T.E., Kiehna E.N., Li C., et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 2006, 65:210-221.
71. Silber J.H., Radcliffe J., Peckham V., et al. Whole-brain irradiation and decline in intelligence: the influence of dose and age on IQ score. J Clin Oncol 1992, 10:1390-1396.
72. Wong C.S., Van der Kogel A.J. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 2004, 4:273-284.
73. Coderre J.A., Morris G.M., Micca P.L., et al. Late effects of radiation on the central nervous system: role of vascular endothelial damage and glial stem cell survival. Radiat Res 2006, 166:495-503.
74. Hong J.H., Chiang C.S., Campbell I.L., et al. Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys 1995, 33:619-626.
75. Chamberlain M.C., Glantz M.J., Chalmers L., et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82:81-83.
76. Brandsma D., Stalpers L., Taal W., et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461.
77. Taal W., Brandsma D., de Bruin H.G., et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113:405-410.
78. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
79. Patel T.R., McHugh B.J., Bi W.L., et al. A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases. AJNR Am J Neuroradiol 2011, 32:1885-1892.
80. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
81. LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995, 31:1049-1091.
82. Lawrence Y.R., Li X.A., el Naqa I., et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010, 76:S20-S27.
83. Wassenberg M.W., Bromberg J.E., Witkamp T.D., et al. White matter lesions and encephalopathy in patients treated for primary central nervous system lymphoma. J Neurooncol 2001, 52:73-80.
84. Shibamoto Y., Baba F., Oda K., et al. Incidence of brain atrophy and decline in mini-mental state examination score after whole-brain radiotherapy in patients with brain metastases: a prospective study. Int J Radiat Oncol Biol Phys 2008, 72:1168-1173.
85. Armstrong C.L., Hunter J.V., Hackney D., et al. MRI changes due to early-delayed conformal radiotherapy and postsurgical effects in patients with brain tumors. Int J Radiat Oncol Biol Phys 2005, 63:56-63.
86. Berrington de Gonzalez A., Curtis R.E., Kry S.F., et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011, 12:353-360.
87. Armstrong C.L., Hunter J.V., Ledakis G.E., et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 2002, 59:40-48.
88. Brown P.D., Buckner J.C., O'Fallon J.R., et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 2003, 21:2519-2524.
89. Surma-aho O., Niemela M., Vilkki J., et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001, 56:1285-1290.
90. Gondi V., Tolakanahalli R., Mehta M.P., et al. Hippocampal-sparing whole-brain radiotherapy: a "how-to" technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010, 78:1244-1252.
91. Li J., Bentzen S.M., Renschler M., et al. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007, 25:1260-1266.
92. Gahramanov S., Raslan A.M., Muldoon L.L., et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011, 79:514-523.
93. Torcuator R., Zuniga R., Mohan Y.S., et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009, 94:63-68.
94. Chuba P.J., Aronin P., Bhambhani K., et al. Hyperbaric oxygen therapy for radiation-induced brain injury in children. Cancer 1997, 80:2005-2012.
95. Khuntia D., Brown P., Li J., et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006, 24:1295-1304.